2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3493 Analytical and clinical validation results of clonoSEQ measurable residual disease (MRD) using cell-free DNA (cfDNA) for patients with large B-cell lymphoma (LBCL)

April Lo, PhD, Kipp Akers, PhD2, Stephanie Eaneff, MSP3, Melissa Curtis, MSc4, Janhavi Moharil, MS5, James Gowen-MacDonald6, Matthew D Keefe, PhD7, Diem-Trang Tran, PhD8, Niles Trigg9, Adam Gaustad, MS10, Jennifer J. Lee, PhD11, Allison Jacob, MS12, Ilan Kirsch, MD, PhD13
1 Adaptive Biotechnologies, Seattle, Washington, United States
2 Adaptive Biotechnologies, Seattle, Washington, United States
3 Adaptive Biotechnologies, Seattle, Washington, United States
4 Adaptive Biotechnologies, Seattle, Washington, United States
5 Adaptive Biotechnologies, Seattle, Washington, United States
6 Adaptive Biotechnologies, Seattle, Washington, United States
7 Adaptive Biotechnologies, Seattle, Washington, United States
8 Adaptive Biotechnologies, Seattle, Washington, United States
9 Adaptive Biotechnologies, Seattle, Washington, United States
10 Adaptive Biotechnologies, Seattle, Washington, United States
11 Adaptive Biotechnologies, Seattle, Washington, United States
12 Adaptive Biotechnologies, Seattle, Washington, United States
13 Adaptive Biotechnologies, Seattle, Washington, United States

Introduction 

Measurable residual disease (MRD) is an emerging prognostic biomarker for LBCL patients. clonoSEQ utilizes next-generation sequencing (NGS) of unique immunoglobulin rearrangements in cfDNA to measure MRD. Updates to the clonoSEQ assay for cfDNA were implemented in March 2025 to improve stability and sensitivity. However, the analytical and clinical validation (AV/CV) of the enhanced version of the assay have not previously been reported; herein, we report the AV and CV characterization of the enhanced assay. Real-world data (RWD) from LBCL clinical practice is used to demonstrate the prognostic value of MRD status at the end of 1L therapy (EOT) and characterize its relationship with PET-CT response. 

Methods 

AV used LBCL patient plasma to characterize the assay limit of detection (LOD), limit of blank (LOB), limit of quantitation, linearity, input limits, precision, sample stability, and robustness to interferents. CV used retrospective, US-based, electronic health record-derived deidentified data from the Flatiron Health Research Database (data cutoff: March 31, 2026) to assess the prognostic value of MRD. The RWD study cohort included patients with LBCL who completed 1L treatment and had an EOT cfDNA MRD result using the updated clonoSEQ assay. A comparison of EOT PET-CT and MRD results was performed in two nested patient subsets: those who received both an EOT MRD and PET-CT 1) within 90 days of EOT and 2) within 14 days of each other. Progression-free survival (PFS) was analyzed using Kaplan–Meier methods, indexing to the later of the EOT MRD and PET-CT, and stratified by test result at EOT. Cox proportional hazard ratios (HR) with associated 95% confidence intervals and likelihood ratio P values were reported after adjusting for key patient-level covariates (sex, IPI score, and LBCL subtype). Among patients with both an EOT PET-CT and MRD result, Cox proportional hazard models were conducted for each response assessment modality. The positive and negative percent agreement (PPA/NPA) of MRD relative to PET-CT was also compared.

Results 

AV experiments in cfDNA demonstrated consistency with clonoSEQ cellular genomic DNA performance, including LOD < 2 DNA templates, LOB = 0, and lower limit of linearity = 1.10 DNA templates.  

RWD analysis of prognostic value utilized 79 real-world LBCL patients who received an EOT MRD test. Patients had a median age of 68 years, were 67% male, and had a median follow-up time of 9.9 months after 1L start. Among patients with known IPI risk scores (n = 29), 52% of patients had high (3-5) and 48% had low (0-2) IPI scores. By subtype, most patients had DLBCL/HGBCL not otherwise specified (82%), while 5% had double-/triple-hit lymphoma and 13% had another DLBCL subtype. The majority of patients received standard of care 1L treatment (60% R/G-CHOP, 24% Pola + R/G-CHP). Among these 79 patients, MRD was strongly predictive of PFS (HR, 27.2; 95% CI, 7.32-100.99; P < .0001). Among patients who received both an MRD and PET-CT test within 90 days of EOT (n = 51), MRD was more predictive of PFS than PET-CT (MRD: HR, 124; P < .0001 vs PET-CT: HR, 7.76; P = .0135). Relative to PET, the PPA was 91%; i.e., 91% of the PET-CT complete responders were MRD not detected, and the NPA was 41%. Among the 10 patients who had PR, PD, or SD but were MRD-negative, treatment was only changed in 2 cases. Results were consistent among the smaller subset of patients (n = 30) who received an EOT MRD and PET within 14 days of each other (MRD: HR > 100; P = .003 vs PET-CT: HR, 17.6; P = .0788). In this cohort, the PPA was 91% and the NPA was 71%. Among the 2 patients who had PR, PD, or SD but were MRD-negative, the treatment had not been changed for either patient.  

Conclusions 

AV results indicate that the updated clonoSEQ assay for cfDNA provides robust and reliable MRD measures across a variety of assay conditions. The RWD analysis represents one of the largest RW clinical practice data sets in LBCL to date and demonstrates the prognostic value of immunoglobulin-based MRD from cfDNA in patients with LBCL. MRD status at 1L EOT was strongly predictive of clinical outcomes, and more so than PET-CT, underscoring the potential for clinical utility of MRD testing at EOT. 

 

April Lo, PhD: Adaptive Biotechnologies - Current Employment